Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Citigroup Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target increased by equities researchers at Citigroup from $338.00 to $351.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's target price indicates a potential upside of 23.83% from the company's previous close.

ALNY has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a "neutral" rating in a report on Tuesday, March 11th. Bank of America lifted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a "sector outperform" rating in a report on Friday. Finally, Royal Bank of Canada increased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Down 2.5 %

NASDAQ ALNY traded down $7.24 during midday trading on Friday, hitting $283.46. 470,032 shares of the company traded hands, compared to its average volume of 806,012. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company's 50-day simple moving average is $257.81 and its 200-day simple moving average is $260.02. The company has a market cap of $36.70 billion, a PE ratio of -131.03 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Allworth Financial LP lifted its position in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 38 shares during the last quarter. Investment Management Corp of Ontario raised its stake in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock valued at $1,670,000 after acquiring an additional 40 shares in the last quarter. Nixon Peabody Trust Co. boosted its position in Alnylam Pharmaceuticals by 1.9% during the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after purchasing an additional 43 shares during the period. Brevan Howard Capital Management LP boosted its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 44 shares during the period. Finally, IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.